Abstract
Regulation of the sleep-waking cycle is complex, involving multiple neurological circuits and diverse endogenous molecules. Interplay among assorted neuroanatomical and neurochemical systems such as acetylcholine, dopamine, noradrenaline, serotonin, histamine, and hypocretin maintain the waking (W) state. The sleep-onset is governed by the interacting forces of the sleep drive, which steadily increases with duration of W, and circadian fluctuations. Sleeppromoting neurons located in the anterior hypothalamus release GABA and inhibit wake-promoting regions in the hypothalamus and brainstem and participate in the generation of slow wave sleep (SWS). During rapid eye movement (REM) sleep, brainstem regions typically inhibited during W and SWS become active. In this regard, ascending projections from cholinergic neurons in the brainstem activate the thalamus which in turn increases the firing of the neurons in the cortex. Finally, sleep-promoting substances that accumulate in the brain during natural or prolonged W implicate a further complexity in the mechanism of modulation of the sleep-wake cycle. This review provides a broad understanding of our present knowledge in the field of sleep research.
Keywords: Sleep-wake cycle, neurotransmitter, brainstem, lateral hypothalamus, cortex, histamine
CNS & Neurological Disorders - Drug Targets
Title: Mechanisms of Sleep-Wake Cycle Modulation
Volume: 8 Issue: 4
Author(s): Eric Murillo-Rodriguez, Oscar Arias-Carrion, Katya Sanguino-Rodriguez, Mauricio Gonzalez-Arias and Reyes Haro
Affiliation:
Keywords: Sleep-wake cycle, neurotransmitter, brainstem, lateral hypothalamus, cortex, histamine
Abstract: Regulation of the sleep-waking cycle is complex, involving multiple neurological circuits and diverse endogenous molecules. Interplay among assorted neuroanatomical and neurochemical systems such as acetylcholine, dopamine, noradrenaline, serotonin, histamine, and hypocretin maintain the waking (W) state. The sleep-onset is governed by the interacting forces of the sleep drive, which steadily increases with duration of W, and circadian fluctuations. Sleeppromoting neurons located in the anterior hypothalamus release GABA and inhibit wake-promoting regions in the hypothalamus and brainstem and participate in the generation of slow wave sleep (SWS). During rapid eye movement (REM) sleep, brainstem regions typically inhibited during W and SWS become active. In this regard, ascending projections from cholinergic neurons in the brainstem activate the thalamus which in turn increases the firing of the neurons in the cortex. Finally, sleep-promoting substances that accumulate in the brain during natural or prolonged W implicate a further complexity in the mechanism of modulation of the sleep-wake cycle. This review provides a broad understanding of our present knowledge in the field of sleep research.
Export Options
About this article
Cite this article as:
Murillo-Rodriguez Eric, Arias-Carrion Oscar, Sanguino-Rodriguez Katya, Gonzalez-Arias Mauricio and Haro Reyes, Mechanisms of Sleep-Wake Cycle Modulation, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921654
DOI https://dx.doi.org/10.2174/187152709788921654 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bilirubin and the Genome: The Hereditary Basis of Unconjugated Neonatal Hyperbilirubinemia
Current Pharmacogenomics One Decade Later: What has Gene Expression Profiling Told us About Neuronal Cell Types, Brain Function and Disease?
Current Genomics Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Mixed Lineage Kinase Family, Potential Targets for Preventing Neurodegeneration
Current Medicinal Chemistry - Central Nervous System Agents C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression
Current Pharmaceutical Design Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Perinatal Brain Injury
Current Pediatric Reviews The Relationship of Developmental Changes in White Matter to the Onset of Psychosis
Current Pharmaceutical Design Neurokinin 3 (NK3) Receptor Modulators for the Treatment of Psychiatric Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology Growth Factors and Chemokines: A Comparative Functional Approach Between Invertebrates and Vertebrates
Current Medicinal Chemistry Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease
Current Drug Targets